Regulation of post-translational modification of PD-L1 and associated opportunities for novel small-molecule...

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Programmed death-ligand 1 (PD-L1) overexpression on tumor cells facilitates immune evasion by binding to PD-1.
• Current therapeutic strategies targeting the PD-1/PD-L1 pathway, such as immune checkpoint inhibitors, have limitations due to PD-L1's cytoplasmic presence.
• Post-translational modifications (PTMs) of PD-L1 play critical roles in various cancers.

Purpose of the Study:

• To summarize the diverse post-translational modifications (PTMs) of PD-L1.
• To explore the regulatory mechanisms of small molecule inhibitors in carcinogenesis related to PD-L1.
• To propose novel therapeutic strategies for tumor immunotherapy based on PD-L1 PTMs.

Main Methods:

• Literature review of PD-L1 post-translational modifications.
• Analysis of small molecule inhibitors' mechanisms in cancer signaling pathways.
• Synthesis of current knowledge on PD-L1 regulation and therapeutic targeting.

Main Results:

• PD-L1 PTMs reveal multiple mechanisms contributing to cancer development.
• Small molecule inhibitors can effectively block key carcinogenic signaling pathways involving PD-L1.
• Cytoplasmic PD-L1 and its PTMs present therapeutic opportunities.

Conclusions:

• Targeting PD-L1 PTMs with small molecule inhibitors represents a promising avenue for overcoming limitations of current immunotherapies.
• A deeper understanding of PD-L1 PTMs is crucial for developing more effective cancer treatments.
• This review provides a framework for novel small molecule inhibitor development in tumor immunotherapy.